|
1
|
Kumar S, Srivastava VK, Kaushik S, Saxena
J and Jyoti A: Free radicals, mitochondrial dysfunction and
sepsis-induced organ dysfunction: A mechanistic insight. Curr Pharm
Des. 30:161–168. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lelubre C and Vincent JL: Mechanisms and
treatment of organ failure in sepsis. Nat Rev Nephrol. 14:417–427.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keating GM: Dexmedetomidine: A review of
its use for sedation in the intensive care setting. Drugs.
75:1119–1130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon WH, Ling RR, Yang IX, Luo H, Kofidis
T, MacLaren G, Tham C, Teoh KLK and Ramanathan K: Dexmedetomidine
for adult cardiac surgery: A systematic review, meta-analysis and
trial sequential analysis. Anesthesia. 78:371–380. 2023. View Article : Google Scholar
|
|
5
|
Zhang DF, Su X, Meng ZT, Li HL, Wang DX,
Xue-Ying Li, Maze M and Ma D: Impact of dexmedetomidine on
long-term outcomes after noncardiac surgery in elderly: 3-Year
follow-up of a randomized controlled trial. Ann Surg. 270:356–363.
2019. View Article : Google Scholar
|
|
6
|
Sun YB, Zhao H, Mu DL, Zhang W, Cui J, Wu
L, Alam A, Wang DX and Ma D: Dexmedetomidine inhibits astrocyte
pyroptosis and subsequently protects the brain in in vitro and in
vivo models of sepsis. Cell Death Dis. 10:1672019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cui J, Zhao H, Yi B, Zeng J, Lu K and Ma
D: Dexmedetomidine attenuates bilirubin-induced lung alveolar
epithelial cell death in vitro and in vivo. Crit Care Med.
43:e356–e368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mei B, Li J and Zuo Z: Dexmedetomidine
attenuates sepsis-associated inflammation and encephalopathy via
central α2A adrenoceptor. Brain Behav Immun. 91:296–314. 2021.
View Article : Google Scholar
|
|
9
|
Bo JH, Wang JX, Wang XL, Jiao Y, Jiang M,
Chen JL, Hao WY, Chen Q, Li YH, Ma ZL and Zhu GQ: Dexmedetomidine
attenuates lipopolysaccharide-induced sympathetic activation and
sepsis via suppressing superoxide signaling in paraventricular
nucleus. Antioxidants (Basel). 11:23952022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma S, Evans RG, Iguchi N, Tare M,
Parkington HC, Bellomo R, May CN and Lankadeva YR: Sepsis-induced
acute kidney injury: A disease of the microcirculation.
Microcirculation. 26:e124832019. View Article : Google Scholar
|
|
11
|
Carnicelli P, Otsuki DA, Filho AM,
Kahvegian MAP, Ida KK, Auler JOC Jr, Rouby JJ and Fantoni DT:
Effects of dexmedetomidine on hemodynamic, oxygenation,
microcirculation, and inflammatory markers in a porcine model of
sepsis. Acta Cir Bras. 37:e3707032022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rudd KE, Johnson SC, Agesa KM, Shackelford
KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer
S, et al: Global, regional, and national sepsis incidence and
mortality, 1990-2017: Analysis for the global burden of disease
study. Lancet. 395:200–211. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arefian H, Heublein S, Scherag A,
Brunkhorst FM, Younis MZ, Moerer O, Fischer D and Hartmann M:
Hospital-related cost of sepsis: A systematic review. J Infect.
74:107–117. 2017. View Article : Google Scholar
|
|
14
|
Zhou J, Tian H, Du X, Xi X, An Y, Duan M,
Weng L and Du B; for China Critical Care Clinical Trials Group
(CCCCTG): Population-based epidemiology of sepsis in a Subdistrict
of Beijing. Crit Care Med. 45:1168–1176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Lin Y, Zhang Z, Chen Y and Zhong
J: Immune regulation and organ damage link adiponectin to sepsis.
Front Immunol. 15:14448842024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caraballo C and Jaimes F: Organ
dysfunction in sepsis: An ominous trajectory from infection to
death. Yale J Biol Med. 92:629–640. 2019.PubMed/NCBI
|
|
17
|
Killien EY, Zahlan JM, Lad H, Watson RS,
Vavilala MS, Huijsmans RLN and Rivara FP: Epidemiology and outcomes
of multiple organ dysfunction syndrome following pediatric trauma.
J Trauma Acute Care Surg. 93:829–837. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fleiss N and Polin RA: Sequential organ
failure assessment scores to predict outcomes: From adults to
neonates. Curr Opin Pediatr. 35:218–222. 2023. View Article : Google Scholar
|
|
19
|
Nair AS, Saifuddin MS, Naik V and Rayani
BK: Dexmedetomidine in cancer surgeries: Present status and
consequences with its use. Indian J Cancer. 57:234–238. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weerink MAS, Struys MMRF, Hannivoort LN,
Barends CRM, Absalom AR and Colin P: Clinical pharmacokinetics and
pharmacodynamics of dexmedetomidine. Clin Pharmacokinet.
56:893–913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Behera BK, Misra S, Jena SS and Mohanty
CR: The effect of perioperative dexmedetomidine on postoperative
bowel function recovery in adult patients receiving general
anesthesia. Minerva Anestesiol. 88:51–61. 2022. View Article : Google Scholar
|
|
22
|
Benet LZ and Hoener BA: Changes in plasma
protein binding have little clinical relevance. Clin Pharmacol
Ther. 71:115–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gagnon DJ, Riker RR, Glisic EK, Kelner A,
Perrey HM and Fraser GL: Transition from dexmedetomidine to enteral
clonidine for ICU sedation: An observational pilot study.
Pharmacotherapy. 35:251–259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sleigh JW, Vacas S, Flexman AM and Talke
PO: Electroencephalographic arousal patterns under dexmedetomidine
sedation. Anesth Analg. 127:951–959. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding J, Chen Y and Gao Y: Effect of
propofol, midazolam and dexmedetomidine on ICU patients with sepsis
and on arterial blood gas. Exp Ther Med. 18:4340–4346.
2019.PubMed/NCBI
|
|
26
|
Kawazoe Y, Miyamoto K, Morimoto T,
Yamamoto T, Fuke A, Hashimoto A, Koami H, Beppu S, Katayama Y, Itoh
M, et al: Effect of dexmedetomidine on mortality and
ventilator-free days in patients requiring mechanical ventilation
with sepsis: A randomized clinical trial. JAMA. 317:1321–1328.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miller JW, Balyan R, Dong M, Mahmoud M,
Lam JE, Pratap JN, Paquin JR, Li BL, Spaeth JP, Vinks A and Loepke
AW: Does intranasal dexmedetomidine provide adequate plasma
concentrations for sedation in children: A pharmacokinetic study.
Br J Anaesth. 120:1056–1065. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yadav S and Ramdas E: Intranasal
dexmedetomidine versus oral midazolam for premedication in
pediatric anesthesia: A prospective double-blinded randomized
controlled study. Anesth Analg. 123(3S_Suppl): S3552016. View Article : Google Scholar
|
|
29
|
Murphy KS, Golden JC and Tampi RR:
Dexmedetomidine for agitation in dementia: Current data and future
direction. J Am Geriatr Soc. 73:552–557. 2025. View Article : Google Scholar
|
|
30
|
Scheckenbach V and Fideler F: Optimizing
pediatric sedation: Evaluating remimazolam and dexmedetomidine for
safety and efficacy in clinical practice. Paediatr Drugs.
27:181–189. 2025. View Article : Google Scholar :
|
|
31
|
Buckley MS, Smithburger PL, Wong A, Fraser
GL, Reade MC, Klein-Fedyshin M, Ardiles T and Kane-Gill SL:
Dexmedetomidine for facilitating mechanical ventilation extubation
in difficult-to-wean ICU patients: Systematic review and
meta-analysis of clinical trials. J Intensive Care Med. 36:925–936.
2021. View Article : Google Scholar
|
|
32
|
Khan A, Sinha R, Kumar KR, Velpandian T,
Maitra S and Ray BR: Comparison of plasma concentration and
sedative effect of sublingual and intranasal dexmedetomidine in
children: A double-blind randomized controlled study. Acta
Anesthesiol Scand. 69:e145832025. View Article : Google Scholar
|
|
33
|
Portelli K, Kandraju H, Ryu M and Shah PS:
Efficacy and safety of dexmedetomidine for analgesia and sedation
in neonates: A systematic review. J Perinatol. 44:164–172. 2024.
View Article : Google Scholar
|
|
34
|
Lim JY, Ker CJ, Lai NM, Romantsik O,
Fiander M and Tan K: Dexmedetomidine for analgesia and sedation in
newborn infants receiving mechanical ventilation. Cochrane Database
Syst Rev. 5:CD0123612024.PubMed/NCBI
|
|
35
|
Kayki G, Yalcin N, Celik HT and Yigit S:
Dexmedetomidine in neonates: Utilisation trends and safety profile
over time in a neonatal intensive care unit. BMJ Paediatr Open.
9:e0030042025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji SJ, Qian ZH, Hu PY and Chen FY:
Age-dependent changes in skeletal muscle mass and visceral fat area
in a Chinese Population. Curr Med Sci. 43:838–844. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bucław M, Majewska D, Szczerbińska D and
Ligocki M: The influence of age and gender on emu (Dromaius
novaehollandiae) fat. Sci Rep. 10:110822020. View Article : Google Scholar
|
|
38
|
Degrassi I, Leonardi I, Di Profio E,
Montanari C, Zuccotti G and Verduci E: Fat-Soluble vitamins
deficiency in pediatric cholestasis: A scoping review. Nutrients.
15:24912023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang Y, Feng J, Xu J, Dong L, Su W, Li B,
Witwer KW and Zheng L: Associations of age and sex with
characteristics of extracellular vesicles and protein-enriched
fractions of blood plasma. Aging Cell. 24:e143562025. View Article : Google Scholar
|
|
40
|
Peixoto TC, Quitete FT, Teixeira AVS,
Martins BC, Soares RA, Atella GC, Bertasso IM, Lisboa PC, Resende
AC, Mucci DB, et al: Palm and interesterified palm oil-enhanced
brown fat whitening contributes to metabolic dysfunction in
C57BL/6J mice. Nutr Res. 133:94–107. 2025. View Article : Google Scholar
|
|
41
|
Zhao S, Zhou R, Zhong Q and Zhang M:
Effect of age and ICU types on mortality in invasive mechanically
ventilated patients with sepsis receiving dexmedetomidine: A
retrospective cohort study with propensity score matching. Front
Pharmacol. 15:13443272024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Venn RM, Karol MD and Grounds RM:
Pharmacokinetics of dexmedetomidine infusions for sedation of
postoperative patients requiring intensive caret. Br J Anaesth.
88:669–675. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hart CG, Voelz BE, Brockus KE and Lemley
CO: Hepatic steroid inactivating enzymes, hepatic portal blood flow
and corpus luteum blood perfusion in cattle. Reprod Domest Anim.
53:751–758. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin L, Guo X, Zhang MZ, Qu CJ, Sun Y and
Bai J: Pharmacokinetics of dexmedetomidine in Chinese post-surgical
intensive care unit patients. Acta Anesthesiol Scand. 55:359–367.
2011. View Article : Google Scholar
|
|
45
|
Iirola T, Laitio R, Kentala E, Aantaa R,
Kurvinen JP, Scheinin M and Olkkola KT: Highly variable
pharmacokinetics of dexmedetomidine during intensive care: A case
report. J Med Case Rep. 25:732010. View Article : Google Scholar
|
|
46
|
Yang L, Zhu L, Qi B, Zhang Y, Ni C, Zhang
Y, Shi X, Xia Q, Masters J, Ma D and Yu W: Dexmedetomidine use
during orthotopic liver transplantation surgery on early allograft
dysfunction: A randomized controlled trial. Int J Surg.
110:5518–5526. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ustun YB, Koksal E, Turunc E, Komurcu O,
Dost B, Ozsay O and Karabulut K: Early extubation after liver
transplantation: Is dexmedetomidine a good option?: A retrospective
cohort study. Int J Clin Pract. 75:e146292021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu H, An S, Sha T, Wu F, Jin Y, Li L, Zeng
Z, Wu J and Chen Z: Association between dexmedetomidine
administration and outcomes in critically ill patients with
sepsis-associated acute kidney injury. J Clin Anesth.
83:1109602022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Evans RG, Iguchi N, Cochrane AD, Marino B,
Hood SG, Bellomo R, McCall PR, May CN and Lankadeva YR: Renal
hemodynamics and oxygenation during experimental cardiopulmonary
bypass in sheep under total intravenous anesthesia. Am J Physiol
Regul Integr Comp Physiol. 318:R206–R213. 2020. View Article : Google Scholar :
|
|
50
|
Neumann MM, Davio MB, Macknet MR and
Applegate RL II: Dexmedetomidine for awake fiberoptic intubation in
a parturient with spinal muscular atrophy type III for cesarean
delivery. Int J Obstet Anesth. 18:403–407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aghamiri SM, Samimi AS, Hajian M, Samimi
AM and Oroumieh A: Effect of xylazine, detomidine, medetomidine and
dexmedetomidine during laparoscopic SCNT embryo transfer on
pregnancy rate and some physiological variables in goats. BMC Vet
Res. 18:982022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang K, Wu M, Xu J, Wu C, Zhang B, Wang G
and Ma D: Effects of dexmedetomidine on perioperative stress,
inflammation, and immune function: Systematic review and
meta-analysis. Br J Anaesth. 123:777–794. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen M, Li X and Mu G: Myocardial
protective and anti-inflammatory effects of dexmedetomidine in
patients undergoing cardiovascular surgery with cardiopulmonary
bypass: A systematic review and meta-analysis. J Anesth. 36:5–16.
2022. View Article : Google Scholar
|
|
54
|
Ma J, Chen Q, Li J, Zhao H, Mi E, Chen Y,
Yi B, Ning J, Ma D, Lu K and Gu J: Dexmedetomidine-mediated
prevention of renal ischemia-reperfusion injury depends in part on
cholinergic anti-inflammatory mechanisms. Anesth Analg.
130:1054–1062. 2020. View Article : Google Scholar
|
|
55
|
Han QQ, Li XY and Wang YX: Dexmedetomidine
attenuates lipopolysaccharide-induced inflammation through
macrophageal IL-10 expression following α7 nAchR activation. Int
Immunopharmacol. 109:1089202022. View Article : Google Scholar
|
|
56
|
Li J, Chen Q, He X, Alam A, Ning J, Yi B,
Lu K and Gu J: Dexmedetomidine attenuates lung apoptosis induced by
renal ischemia-reperfusion injury through α2AR/PI3K/Akt pathway. J
Transl Med. 16:782018. View Article : Google Scholar
|
|
57
|
Wang K and Zhu Y: Dexmedetomidine protects
against oxygen-glucose deprivation/reoxygenation injury-induced
apoptosis via the p38 MAPK/ERK signalling pathway. J Int Med Res.
46:675–686. 2018. View Article : Google Scholar :
|
|
58
|
Zhu Z, Ling X, Zhou H, Zhang C and Yan W:
Dexmedetomidine attenuates cellular injury and apoptosis in H9c2
cardiomyocytes by regulating p-38MAPK and endoplasmic reticulum
stress. Drug Des Dev Ther. 14:4231–4243. 2020. View Article : Google Scholar
|
|
59
|
Deng X, Ye F, Zeng L, Luo W, Tu S, Wang X
and Zhang Z: Dexmedetomidine mitigates myocardial
ischemia/reperfusion-induced mitochondrial apoptosis through
targeting lncRNA HCP5. Am J Chin Med. 50:1529–1551. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wei Q, Chen J, Xiao F, Tu Y, Zhong Y and
Xie Y: High-dose dexmedetomidine promotes apoptosis in fetal rat
hippocampal neurons. Drug Des Dev Ther. 15:2433–2444. 2021.
View Article : Google Scholar
|
|
61
|
Zhang Z, Mu X and Zhou X: Dexmedetomidine
alleviates inflammatory response and oxidative stress injury of
vascular smooth muscle cell via α2AR/GSK-3β/MKP-1/NRF2 axis in
intracranial aneurysm. BMC Pharmacol Toxico. 23:812022. View Article : Google Scholar
|
|
62
|
Choi HI, Kim HJ, Park JS, Kim IJ, Bae EH,
Ma SK and Kim SW: PGC-1α attenuates hydrogen peroxide-induced
apoptotic cell death by upregulating Nrf-2 via GSK3β inactivation
mediated by activated p38 in HK-2 cells. Sci Rep. 7:43192017.
View Article : Google Scholar
|
|
63
|
Zhao Y, Kong GY, Pei WM, Zhou B, Zhang QQ
and Pan BB: Dexmedetomidine alleviates hepatic injury via the
inhibition of oxidative stress and activation of the Nrf2/HO-1
signaling pathway. Eur Cytokine Netw. 30:88–97. 2019. View Article : Google Scholar
|
|
64
|
Chen J, Shen N, Duan X and Guo Y: An
investigation of the mechanism of dexmedetomidine in improving
postoperative cognitive dysfunction from the perspectives of
alleviating neuronal mitochondrial membrane oxidative stress and
electrophysiological dysfunction. Exp Ther Med. 15:2037–2043.
2018.PubMed/NCBI
|
|
65
|
Yu T, Liu D, Gao M, Yang P, Zhang M, Song
F, Zhang X and Liu Y: Dexmedetomidine prevents septic myocardial
dysfunction in rats via activation of α7nAChR and PI3K/Akt-mediated
autophagy. Biomed Pharmacother. 120:1092312019. View Article : Google Scholar
|
|
66
|
Lempiäinen J, Finckenberg P, Mervaala EE,
Storvik M, Kaivola J, Lindstedt K, Levijoki J and Mervaala EM:
Dexmedetomidine preconditioning ameliorates kidney
ischemia-reperfusion injury. Pharmacol Res Perspe. 2:e000452014.
View Article : Google Scholar
|
|
67
|
Li Y, Qu M, Xing F, Li H, Cheng D, Xing N
and Zhang W: The protective mechanism of dexmedetomidine in
regulating Atg14L-Beclin1-Vps34 complex against myocardial
ischemia-reperfusion injury. J Cardiovasc Transl Res. 14:1063–1074.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhu Y, Li S, Liu J, Wen Q, Yu J, Yu L and
Xie K: Role of JNK signaling pathway in dexmedetomidine
post-conditioning-induced reduction of the inflammatory response
and autophagy effect of focal cerebral ischemia reperfusion injury
in rats. Inflammation. 42:2181–2191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Qin W, Zhang X, Yang S, Li Y, Yuan J, Yang
L, Li S and Hu W: Risk factors for multiple organ dysfunction
syndrome in severe stroke patients. PLoS One. 11:e01671892016.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
van der Poll T, Shankar-Hari M and
Wiersinga WJ: The immunology of sepsis. Immunity. 54:2450–2464.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gordon S: Phagocytosis: An immunobiologic
process. Immunity. 44:463–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kumar V: Immunometabolism: Another road to
sepsis and its therapeutic targeting. Inflammation. 42:765–788.
2019. View Article : Google Scholar
|
|
73
|
Hoesel LM, Neff TA, Neff SB, Younger JG,
Olle EW, Gao H, Pianko MJ, Bernacki KD, Sarma JV and Ward PA:
Harmful and protective roles of neutrophils in sepsis. Shock.
24:40–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lu J, Liu J and Li A: Roles of neutrophil
reactive oxygen species (ROS) generation in organ function
impairment in sepsis. J Zhejiang Univ Sci B. 23:437–450. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Christoffersson G, Vågesjö E, Vandooren J,
Lidén M, Massena S, Reinert RB, Brissova M, Powers AC, Opdenakker G
and Phillipson M: VEGF-A recruits a proangiogenic MMP-9-delivering
neutrophil subset that induces angiogenesis in transplanted hypoxic
tissue. Blood. 120:4653–4662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bateman RM, Sharpe MD and Ellis CG:
Bench-to-bedside review: Microvascular dysfunction in
sepsis-hemodynamics, oxygen transport, and nitric oxide. Crit Care.
7:359–373. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang Y, Bai C and Wang X: COPD-associated
vascular pathology: A future targeting area. Expert Rev Respir Med.
2:297–299. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Fein AM and Calalang-Colucci MG: Acute
lung injury and acute respiratory distress syndrome in sepsis and
septic shock. Crit Care Clin. 16:289–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chen G, Hou Y, Li X, Pan R and Zhao D:
Sepsis-induced acute lung injury in young rats is relieved by
calycosin through inactivating the HMGB1/MyD88/NF-κB pathway and
NLRP3 inflammasome. Int Immunopharmacol. 96:1076232021. View Article : Google Scholar
|
|
80
|
Li J, Lu K, Sun F, Tan S, Zhang X, Sheng
W, Hao W, Liu M, Lv W and Han W: Panaxydol attenuates ferroptosis
against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1
pathway. J Transl Med. 19:962021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hou L, Zhang J, Liu Y, Fang H, Liao L,
Wang Z, Yuan J, Wang X, Sun J, Tang B, et al: MitoQ alleviates
LPS-mediated acute lung injury through regulating Nrf2/Drp1
pathway. Free Radic Biol Med. 165:219–228. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wu Y, Liu Y, Huang H, Zhu Y, Zhang Y, Lu F
and Zhou C, Huang L, Li X and Zhou C: Dexmedetomidine inhibits
inflammatory reaction in lung tissues of septic rats by suppressing
TLR4/NF-κB pathway. Mediators Inflamm. 2013:5621542013. View Article : Google Scholar
|
|
83
|
Cui H and Zhang Q: Dexmedetomidine
ameliorates lipopolysaccharide-induced acute lung injury by
inhibiting the PI3K/Akt/FoxO1 signaling pathway. J Anesth.
35:394–404. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Fu C, Dai X, Yang Y, Lin M, Cai Y and Cai
S: Dexmedetomidine attenuates lipopolysaccharide-induced acute lung
injury by inhibiting oxidative stress, mitochondrial dysfunction
and apoptosis in rats. Mol Med Rep. 15:131–138. 2017. View Article : Google Scholar :
|
|
85
|
Shi J, Yu T, Song K, Du S, He S, Hu X, Li
X, Li H, Dong S, Zhang Y, et al: Dexmedetomidine ameliorates
endotoxin-induced acute lung injury in vivo and in vitro by
preserving mitochondrial dynamic equilibrium through the
HIF-1a/HO-1 signaling pathway. Redox Biol. 41:1019542021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Meng L, Li L, Lu S, Li K, Su Z, Wang Y,
Fan X, Li X and Zhao G: The protective effect of dexmedetomidine on
LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB
and PI3K/Akt/mTOR pathways. Mol Immunol. 94:7–17. 2018. View Article : Google Scholar
|
|
87
|
Zhang P, Peng J, Ren YQ, Zheng H and Yan
H: Dexmedetomidine protects against endothelial injury in septic
rats induced by cecal ligation and puncture by decreasing
angiopoietin 2 and increasing vascular endothelial cadherin levels.
Exp Ther Med. 21:1112021. View Article : Google Scholar
|
|
88
|
Wang R, Xie Y, Qiu J and Chen J: The
effects of dexmedetomidine in a rat model of sepsis-induced lung
injury are mediated through the adenosine monophosphate-activated
protein kinase (AMPK)/silent information regulator 1 (SIRT1)
pathway. Med Sci Monit. 26:e9192132020.PubMed/NCBI
|
|
89
|
Peerapornratana S, Manrique-Caballero CL,
Gómez H and Kellum JA: Acute kidney injury from sepsis: Current
concepts, epidemiology, pathophysiology, prevention and treatment.
Kidney Int. 96:1083–1099. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Manrique-Caballero CL, Del Rio-Pertuz G
and Gomez H: Sepsis-associated acute kidney injury. Crit Care Clin.
37:279–301. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Hu X, Zhou W, Wu S, Wang R, Luan Z, Geng
X, Xu N, Zhang Z, Ruan Z, Wang Z, et al: Tacrolimus alleviates
LPS-induced AKI by inhibiting TLR4/MyD88/NF-κB signalling in mice.
J Cell Mol Med. 26:507–514. 2022. View Article : Google Scholar
|
|
92
|
Huang G, Bao J, Shao X, Zhou W, Wu B, Ni Z
and Wang L: Inhibiting pannexin-1 alleviates sepsis-induced acute
kidney injury via decreasing NLRP3 inflammasome activation and cell
apoptosis. Life Sci. 254:1177912020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li J, Wang L, Wang B, Zhang Z, Jiang L,
Qin Z, Zhao Y and Su B: NOX4 is a potential therapeutic target in
septic acute kidney injury by inhibiting mitochondrial dysfunction
and inflammation. Theranostics. 13:2863–2878. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Liu W, Yu W, Weng Y, Wang Y and Sheng M:
Dexmedetomidine ameliorates the inflammatory immune response in
rats with acute kidney damage. Exp Ther Med. 14:3602–3608. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Jin YH, Li ZT, Chen H, Jiang XQ, Zhang YY
and Wu F: Effect of dexmedetomidine on kidney injury in sepsis rats
through TLR4/MyD88/NF-κB/iNOS signaling pathway. Eur Rev Med
Pharmacol Sci. 23:5020–5025. 2019.PubMed/NCBI
|
|
96
|
Yao Y, Hu X, Feng X, Zhao Y, Song M, Wang
C and Fan H: Dexmedetomidine alleviates lipopolysaccharide-induced
acute kidney injury by inhibiting the NLRP3 inflammasome activation
via regulating the TLR4/NOX4/NF-κB pathway. J Cell Biochem.
120:18509–18523. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang Z, Wu J, Hu Z, Luo C, Wang P, Zhang Y
and Li H: Dexmedetomidine alleviates lipopolysaccharide-induced
acute kidney injury by inhibiting p75NTR-mediated oxidative stress
and apoptosis. Oxid Med Cell Longev. 2020:54542102020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhao Y, Feng X, Li B, Sha J, Wang C, Yang
T, Cui H and Fan H: Dexmedetomidine protects against
lipopolysaccharide-induced acute kidney injury by enhancing
autophagy through inhibition of the PI3K/AKT/mTOR pathway. Front
Pharmacol. 11:1282020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kim TS and Choi DH: Liver dysfunction in
sepsis. Korean J Gastroenterol. 75:182–187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Cai Y, Zhao D, Pan Y, Chen B, Cao Y, Han
S, Lian F, Zhang Y and Yan X: Gallic acid attenuates sepsis-induced
liver injury through C/EBPbeta-dependent MAPK signaling pathway.
Mol Nutr Food Res. 29:e24001232024. View Article : Google Scholar
|
|
101
|
Ou Z, Zhong H, Zhang L, Deng M, Zhang W,
Wang J, Feng H, Gong J, Miao C and Yi Z: Macrophage membrane-coated
nanoparticles alleviate hepatic ischemia-reperfusion injury caused
by orthotopic liver transplantation by neutralizing endotoxin. Int
J Nanomedicine. 15:4125–4138. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Song H, Zhang X, Zhai R, Liang H, Song G,
Yuan Y, Xu Y, Yan Y, Qiu L and Sun T: Metformin attenuated
sepsis-associated liver injury and inflammatory response in aged
mice. Bioengineered. 13:4598–4609. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hong KS, Kim NR, Song SH and Hong G:
Cycling of dexmedetomidine may prevent delirium after liver
transplantation. Transplant Proc. 50:1080–1082. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tong F, Shen W, Song P, Song J, Hu Y, Liu
F, Meng Z and Liu J: Dexmedetomidine attenuates
lipopolysaccharide-induced acute liver injury in rats by inhibiting
caveolin-1 downstream signaling pathway. Biosci Rep.
41:BSR202042792021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zi SF, Li JH, Liu L, Deng C, Ao X, Chen DD
and Wu SZ: Dexmedetomidine-mediated protection against septic liver
injury depends on TLR4/MyD88/NF-κB signaling downregulation partly
via cholinergic anti-inflammatory mechanisms. Int Immunopharmacol.
76:1058982019. View Article : Google Scholar
|
|
106
|
Yu Q, Zou L, Yuan X, Fang F and Xu F:
Dexmedetomidine protects against septic liver injury by enhancing
autophagy through activation of the AMPK/SIRT1 signaling pathway.
Front Pharmacol. 12:6586772021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sha J, Zhang H, Zhao Y, Feng X, Hu X, Wang
C, Song M and Fan H: Dexmedetomidine attenuates
lipopolysaccharide-induced liver oxidative stress and cell
apoptosis in rats by increasing GSK-3β/MKP-1/Nrf2 pathway activity
via the α2 adrenergic receptor. Toxicol Appl Pharmacol.
364:144–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhou H, Sun J, Zhong W, Pan X, Liu C,
Cheng F, Wang P and Rao Z: Dexmedetomidine preconditioning
alleviated murine liver ischemia and reperfusion injury by
promoting macrophage M2 activation via PPARγ/STAT3 signaling. Int
Immunopharmacol. 82:1063632020. View Article : Google Scholar
|
|
109
|
Frencken JF, Donker DW, Spitoni C,
Koster-Brouwer ME, Soliman IW, Ong DSY, Horn J, van der Poll T, van
Klei WA, Bonten MJM and Cremer OL: Myocardial injury in patients
with sepsis and its association with long-term outcome. Circ
Cardiovasc Qual Outcomes. 11:e0040402018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Orde SR, Pulido JN, Masaki M, Gillespie S,
Spoon JN, Kane GC and Oh JK: Outcome prediction in sepsis: Speckle
tracking echocardiography based assessment of myocardial function.
Crit Care. 18:R1492014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Maeder M, Fehr T, Rickli H and Ammann P:
Sepsis-associated myocardial dysfunction: Diagnostic and prognostic
impact of cardiac troponins and natriuretic peptides. Chest.
129:1349–1366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Sun F, Xu K, Zhou J, Zhang W, Duan G and
Lei M: Allicin protects against LPS-induced cardiomyocyte injury by
activating Nrf2-HO-1 and inhibiting NLRP3 pathways. BMC Cardiovasc
Disord. 23:4102023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wang Y, Feng W, Li S, Liu C, Jia L, Wang
P, Li L, Du H and Yu W: Oxycodone attenuates
lipopolysaccharide-induced myocardial injury by inhibiting
inflammation, oxidation and pyroptosis via Nrf2/HO-1 signalling
pathway. Clin Exp Pharmacol Physiol. 51:e139102024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Lu C, Liu J, Escames G, Yang Y, Wu X, Liu
Q, Chen J, Song Y, Wang Z, Deng C, et al: PIK3CG regulates NLRP3/
GSDMD-mediated pyroptosis in septic myocardial injury.
Inflammation. 46:2416–2432. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Bi CF, Liu J, Yang LS and Zhang JF:
Research progress on the mechanism of sepsis induced myocardial
injury. J Inflamm Res. 15:4275–4290. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Taniguchi T, Kurita A, Kobayashi K,
Yamamoto K and Inaba H: Dose- and time-related effects of
dexmedetomidine on mortality and inflammatory responses to
endotoxin-induced shock in rats. J Anesth. 22:221–228. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Taniguchi T, Kidani Y, Kanakura H,
Takemoto Y and Yamamoto K: Effects of dexmedetomidine on mortality
rate and inflammatory responses to endotoxin-induced shock in rats.
Crit Care Med. 32:1322–1326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kong W, Kang K, Gao Y, Liu H, Meng X, Yang
S, Yu K and Zhao M: Dexmedetomidine alleviates LPS-induced septic
cardiomyopathy via the cholinergic anti-inflammatory pathway in
mice. Am J Transl Res. 9:5040–5047. 2017.PubMed/NCBI
|
|
119
|
Wang C, Yuan W, Hu A, Lin J, Xia Z, Yang
CF, Li Y and Zhang Z: Dexmedetomidine alleviated sepsis-induced
myocardial ferroptosis and septic heart injury. Mol Med Rep.
22:175–184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang T, Mei Q, Dai S, Liu Y and Zhu H:
Use of dexmedetomidine in patients with sepsis: A systematic review
and meta-analysis of randomized-controlled trials. Ann Intensive
Care. 12:812022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Pool R, Gomez H and Kellum JA: Mechanisms
of organ dysfunction in sepsis. Crit Care Clin. 34:63–80. 2018.
View Article : Google Scholar
|
|
122
|
Haussner F, Chakraborty S, Halbgebauer R
and Huber-Lang M: Challenge to the intestinal mucosa during sepsis.
Front Immunol. 10:8912019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Rowlands BJ, Soong CV and Gardiner KR: The
gastrointestinal tract as a barrier in sepsis. Br Med Bull.
55:196–211. 1999. View Article : Google Scholar
|
|
124
|
Chen Y, Miao L, Yao Y, Wu W, Wu X, Gong C,
Qiu L and Chen J: Dexmedetomidine ameliorate CLP-induced rat
intestinal injury via inhibition of inflammation. Mediators
Inflamm. 2015:9183612015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Qin C, Jiang Y, Chen X, Bian Y, Wang Y,
Xie K and Yu Y: Dexmedetomidine protects against burn-induced
intestinal barrier injury via the MLCK/p-MLC signalling pathway.
Burns. 47:1576–1585. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yang J, Wu Y, Xu Y, Jia J, Xi W, Deng H
and Tu W: Dexmedetomidine resists intestinal Ischemia-reperfusion
injury by inhibiting TLR4/MyD88/NF-κB signaling. J Surg Res.
260:350–358. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ye X, Xu H and Yuan X: Dexmedetomidine
alleviates intestinal barrier dysfunction and inflammatory response
in mice via suppressing TLR4/MyD88/NF-κB signaling in an
experimental model of ulcerative colitis. Folia Histochem Cytobiol.
60:311–322. 2022. View Article : Google Scholar
|
|
128
|
Zhang Q, Liu XM, Hu Q, Liu ZR, Liu ZY,
Zhang HG, Huang YL, Chen QH, Wang WX and Zhang XK: Dexmedetomidine
inhibits mitochondria damage and apoptosis of enteric glial cells
in experimental intestinal ischemia/reperfusion injury via
SIRT3-dependent PINK1/HDAC3/p53 pathway. J Transl Med. 19:4632021.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Dong YH, Hu JJ, Deng F, Chen XD, Li C, Liu
KX and Zhao BC: Use of dexmedetomidine to alleviate intestinal
ischemia-reperfusion injury via intestinal microbiota modulation in
mice. Ann Transl Med. 10:11612022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Xu L, Li T, Chen Q, Liu Z, Chen Y, Hu K
and Zhang X: The α2AR/Caveolin-1/p38MAPK/NF-κB axis explains
dexmedetomidine protection against lung injury following intestinal
ischaemia-reperfusion. J Cell Mol Med. 25:6361–6372. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Chang H, Li S, Li Y, Hu H, Cheng B, Miao
J, Gao H, Ma H, Gao Y and Wang Q: Effect of sedation with
dexmedetomidine or propofol on gastrointestinal motility
inlipopolysaccharide-induced endotoxemic mice. BMC Anesthesiol.
20:2272020. View Article : Google Scholar
|
|
132
|
Zhao L, Gao Y, Guo S, Lu X, Yu S, Ge ZZ,
Zhu HD and Li Y: Sepsis-associated encephalopathy: Insight into
injury and pathogenesis. CNS Neurol Disord Drug Targets.
20:112–124. 2021.
|
|
133
|
Subhramanyam CS, Wang C, Hu Q and Dheen
ST: Microglia-mediated neuroinflammation in neurodegenerative
diseases. Semin Cell Dev Biol. 94:112–120. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bao Y, Zhu Y, He G, Ni H, Liu C, Ma L,
Zhang L and Shi D: Dexmedetomidine attenuates neuroinflammation in
LPS-stimulated BV2 microglia cells through upregulation Of miR-340.
Drug Des Devel Ther. 13:3465–3475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
He G, He Y, Ni H, Wang K, Zhu Y and Bao Y:
Dexmedetomidine attenuates neuroinflammation and microglia
activation in LPS-stimulated BV2 microglia cells through targeting
circ-Shank3/miR-140-3p/TLR4 axis. Eur J Histochem. 67:37662023.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lei S, Lu P, Lu Y, Zheng J, Li W, Wang N,
Zhang H, Li R, Wang K, Wen J, et al: Dexmedetomidine alleviates
neurogenesis damage following neonatal midazolam exposure in rats
through JNK and P38 MAPK pathways. ACS Chem Neurosci. 11:579–591.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sun Z, Lin Y, Li Y, Ren T, Du G, Wang J,
Jin X and Yang LC: The effect of dexmedetomidine on inflammatory
inhibition and microglial polarization in BV-2 cells. Neurol Res.
40:838–846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Hamers L, Kox M and Pickkers P:
Sepsis-induced immunoparalysis: Mechanisms, markers, and treatment
options. Minerva Anestesiol. 81:426–439. 2015.
|
|
139
|
Martin MD, Badovinac VP and Griffith TS:
CD4 T cell responses and the sepsis-induced immunoparalysis state.
Front Immunol. 11:13642020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Łysenko L, Leśnik P, Nelke K and Gerber H:
Immune disorders in sepsis and their treatment as a significant
problem of modern intensive care. Postepy Hig Med Dosw (Online).
71:703–712. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lee JM, Han HJ, Choi WK, Yoo S, Baek S and
Lee J: Immunomodulatory effects of intraoperative dexmedetomidine
on T helper 1, T helper 2, T helper 17 and regulatory T cells
cytokine levels and their balance: A prospective, randomised,
double-blind, dose-response clinical study. BMC Anesthesiol.
18:1642018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Yang XH, Bai Q, LvMM, Fu HG, Dong TL and
Zhou Z: Effect of dexmedetomidine on Immune function of patients
undergoing radical mastectomy: A double blind and placebo control
study. Eur Rev Med Pharmacol Sci. 21:1112–1116. 2017.PubMed/NCBI
|
|
143
|
Biccard BM, Goga S and de Beurs J:
Dexmedetomidine and cardiac protection for non-cardiac surgery: A
meta-analysis of randomised controlled trials. Anaesthesia.
63:4–14. 2008. View Article : Google Scholar
|
|
144
|
Farouk I, Hassan MM, Fetouh AM, Elgayed
AEA, Eldin MH and Abdelhamid BM: Analgesic and hemodynamic effects
of intravenous infusion of magnesium sulphate versus
dexmedetomidine in patients undergoing bilateral inguinal hernial
surgeries under spinal anesthesia: A randomized controlled study.
Braz J Anesthesiol. 71:489–497. 2021.PubMed/NCBI
|
|
145
|
Lankadeva YR, Kosaka J, Evans RG, Bailey
SR, Bellomo R and May CN: Intrarenal and urinary oxygenation during
norepinephrine resuscitationin ovine septic acute kidney injury.
Kidney Int. 90:100–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Julien C, Oréa V, Quintin L, Piriou V and
Barrès C: Renal sympathetic nerve activity and vascular reactivity
to phenylephrine after lipopolysaccharide administration in
conscious rats. Physiol Rep. 5:e131392017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Morelli A, Sanfilippo F, Arnemann P,
Hessler M, Kampmeier TG, D'Egidio A, Orecchioni A, Santonocito C,
Frati G, Greco E, et al: The effect of propofol and dexmedetomidine
sedation on norepinephrine requirements in septic shock patients: A
crossover trial. Crit Care Med. 47:e89–e95. 2019. View Article : Google Scholar
|
|
148
|
Lankadeva YR, Ma S, Iguchi N, Evans RG,
Hood SG, Farmer DGS, Bailey SR, Bellomo R and May CN:
Dexmedetomidine reduces norepinephrine requirements and preserves
renal oxygenation and function in ovine septic acute kidney injury.
Kidney Int. 96:1150–1161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yao L, Liu B, He T and Shen F: Comparative
study of dexmedetomidine vs. midazolam on plasma catecholamine
levels and hemodynamics in patients with septic shock. Zhonghua Wei
Zhong Bing Ji Jiu Yi Xue. 33:1193–1197. 2021.In Chinese. PubMed/NCBI
|
|
150
|
Moore ACM, Kachare SD, Barber DA, Barrow L
and O'Daniel TG: Total intravenous anesthesia with dexmedetomidine
for hemodynamic stability and enhanced recovery in facial aesthetic
surgery. Aesthet Surg J. 42:NP602–NP610. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Hazrati E, Vosoughi F, Chamanara M and
Teymourian H: Effect of dexmedetomidine infusion during hip
fracture surgery on hemodynamic parameters and blood loss: A
triple-blinded randomized clinical trial. Injury. 53:551–554. 2022.
View Article : Google Scholar
|
|
152
|
Joffre J, Hellman J, Ince C and
Ait-Oufella H: Endothelial responses in sepsis. Am J Respir Crit
Care Med. 202:361–370. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Joffre J and Hellman J: Oxidative stress
and endothelial dysfunction in sepsis and acute inflammation.
Antioxid Redox Signal. 35:1291–1307. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Cusack R, Leone M, Rodriguez AH and
Martin-Loeches I: Endothelial Damage And the microcirculation in
critical illness. Biomedicines. 10:31502022. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Dai M, Zhu X, Zeng S, Liu Q, Hu R, Huang
L, Wang Y, Deng J and Yu Q: Dexmedetomidine protects cells from
angiotensin II-induced smooth muscle cell phenotype switch and
endothelial cell dysfunction. Cell Cycle. 22:450–463. 2023.
View Article : Google Scholar :
|
|
156
|
Newton CJ, Ran G, Xie YX, Bilko D,
Burgoyne CH, Adams I, Abidia A, McCollum PT and Atkin SL:
Statin-induced apoptosis of vascular endothelial cells is blocked
by dexamethasone. J Endocrinol. 174:7–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Chai Y, Yu R, Liu Y, Wang S, Yuan D and
Chen J: Dexmedetomidine attenuates monocyte-endothelial adherence
via inhibiting connexin43 on vascular endothelial cells. Mediators
Inflamm. 2020:70398542020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Dong W, Yang H, Cheng M, Zhang X, Yin J,
Zeng Z and Huang G: Dexmedetomidine alleviates pulmonary
ischemia-reperfusion injury through modulating the miR-21-5p/Nr4a1
signaling pathway. Acta Biochim Pol. 67:521–529. 2020.PubMed/NCBI
|
|
159
|
Han J, Liu X and Wang L: Dexmedetomidine
protects against acute lung injury in mice via the DUSP1/MAPK/NF-κB
axis by inhibiting miR-152-3p. Pulm Pharmacol Ther. 9:1021312022.
View Article : Google Scholar
|
|
160
|
Zhao Q, Yu S, Ling Y, Hao S and Liu J: The
protective effects of dexmedetomidine against
hypoxia/reoxygenation-induced inflammatory injury and permeability
in brain endothelial cells mediated by sigma-1 receptor. ACS Chem
Neurosci. 12:1940–1947. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zhu Z, Zhou H, Ni Y, Wu C, Zhang C and
Ling X: Can dexmedetomidine reduce atrial fibrillation after
cardiac surgery? A systematic review and meta-analysis. Drug Des
Devel Ther. 12:521–531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Liu X, Xie G, Zhang K, Song S, Song F, Jin
Y and Fang X: Dexmedetomidine vs propofol sedation reduces delirium
in patients after cardiac surgery: A meta analysis with trial
sequential analysis of randomized controlled trials. J Crit Care.
38:190–196. 2017. View Article : Google Scholar
|
|
163
|
Turan A, Duncan A, Leung S, Karimi N, Fang
J, Mao G, Hargrave J, Gillinov M, Trombetta C, Ayad S, et al:
Dexmedetomidine for reduction of atrial fibrillation and delirium
after cardiac surgery(DECADE): A randomised placebo-controlled
trial. Lancet. 396:177–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Hu X, Sun Z, Wang W, Xiao G, Yu Q, Chi L
and Liu H: Dexmedetomidine attenuates isoflurane-induced
neuroapoptosis through the miR-137/GSK-3β pathway in the developing
rat hippocampus. Heliyon. 10:e313722024. View Article : Google Scholar
|
|
165
|
Wu Q, Shang Y, Shen T, Liu F and Zhang W:
Biochanin A protects SH-SY5Y cells against isoflurane-induced
neurotoxicity by suppressing oxidative stress and apoptosis.
Neurotoxicology. 86:10–18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Luo X, Zheng X and Huang H: Protective
effects of dexmedetomidine on brain function of glioma patients
undergoing craniotomy resection and its underlying mechanism. Clin
Neurol Neurosurg. 146:105–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Sanches MC, Bessi WH, Rusch E,
Schaffhausser MB, Cassoli AA, Freitas SH, Gehrcke MI and Carregaro
AB: Cardiopulmonary and propofol-sparing effects of dexmedetomidine
in total intravenous anesthesia in cats undergoing
ovariohysterectomy. J Feline Med Surg. 24:e490–e497. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Liu MJ, Zhao XC, Gong HS, You YQ and Li
JY: Dexmedetomidine prevents hemorrhagic brain injury by reducing
damage induced by ferroptosis in mice. Neurosci Lett.
788:1368422022. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Perez-Zoghbi JF, Zhu W, Grafe MR and
Brambrink AM: Dexmedetomidine-mediated neuroprotection against
sevoflurane-induced neurotoxicity extends to several brain regions
in neonatal rats. Br J Anaesth. 119:506–516. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Goyagi T: Dexmedetomidine reduced
sevoflurane-induced neurodegeneration and long-term memory deficits
in neonatal rats. Int J Dev Neurosci. 75:19–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Sun M, Dong Y, Li M, Zhang Y, Liang F,
Zhang J, Soriano SG and Xie Z: Dexmedetomidine and clonidine
attenuate sevoflurane-induced tau phosphorylation and cognitive
impairment in young mice via α-2 adrenergic receptor. Anesth Analg.
132:878–889. 2021. View Article : Google Scholar :
|
|
172
|
Chai D, Jiang H and Lv X: The impact of
dexmedetomidine on ketamine-induced neurotoxicity and cognitive
impairment in young mice. Int J Dev Neurosci. 84:735–744. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Lv K, Yang C, Xiao R, Yang L, Liu T, Zhang
R and Fan X: Dexmedetomidine attenuates ethanol-induced inhibition
of hippocampal neurogenesis in neonatal mice. Toxicol Appl
Pharmacol. 390:1148812020. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Lee JR, Joseph B, Hofacer RD, Upton B, Lee
SY, Ewing L, Zhang B, Danzer SC and Loepke AW: Effect of
dexmedetomidine on sevoflurane-induced neurodegeneration in
neonatal rats. Br J Anaesth. 126:1009–1021. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Fu Y and Jin Z: Effects of dexmedetomidine
on cognitive function, oxidative stress and brain protection in
patients undergoing craniocerebral surgery. Actas Esp Psiquiatr.
52:19–27. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Shan Y, Yang F, Tang Z, Bi C, Sun S, Zhang
Y and Liu H: Dexmedetomidine ameliorates the neurotoxicity of
sevoflurane on the immature brain through the BMP/SMAD signaling
pathway. Front Neurosci. 12:9642018. View Article : Google Scholar
|
|
177
|
Williams B, Zou L, Pittet JF and Chao W:
Sepsis-Induced coagulopathy: A comprehensive narrative review of
pathophysiology, clinical presentation, diagnosis, and management
strategies. Anesth Analg. 138:696–711. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Chen Z, Zhang H, Qu M, Nan K, Cao H, Cata
JP, Chen W and Miao C: Review: The emerging role of neutrophil
extracellular traps in sepsis and sepsis-associated thrombosis.
Front Cell Infect Microbiol. 11:6532282021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Hagel S, Bach F, Brenner T, Bracht H,
Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, et
al: Effect of therapeutic drug monitoring-based dose optimization
of piperacillin/tazobactam on sepsis-related organ dysfunction in
patients with sepsis: A randomized controlled trial. Intensive Care
Med. 48:311–321. 2022. View Article : Google Scholar : PubMed/NCBI
|
